Scarica l'app Stockscreener
1.13
1.74%
-0.02
Dopo l'orario di chiusura:
1.12
-0.010
-0.88%
Precedente Chiudi:
$1.15
Aprire:
$1.26
Volume 24 ore:
348.45K
Relative Volume:
0.15
Capitalizzazione di mercato:
$15.58M
Reddito:
-
Utile/perdita netta:
$-8.83M
Rapporto P/E:
-1.4293
EPS:
-0.7906
Flusso di cassa netto:
$-8.61M
1 W Prestazione:
-1.74%
1M Prestazione:
-20.98%
6M Prestazione:
+11.88%
1 anno Prestazione:
-22.60%
Intervallo 1D:
$1.13
$1.26
Intervallo di 1 settimana:
$1.08
$1.26
Portata 52W:
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
Nome
Cocrystal Pharma Inc
Settore
Industria
Telefono
(786) 459-1831
Indirizzo
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.13 | 15.86M | 0 | -8.83M | -8.61M | -0.7906 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-08 | Iniziato | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Borsa (COCP) Ultime notizie
Cocrystal Pharma Reports Promising Pan-Viral Antiviral Activity - TipRanks
Cocrystal Pharma (COCP) Unveils Promising Antiviral Developments - GuruFocus
Cocrystal Pharma discovers new pan-viral inhibitors - BioWorld News
Cocrystal Pharma (NASDAQ: COCP) highlights pan-viral inhibitor data and Phase 1b progress - Stock Titan
Deadly cruise ship hantavirus; Cocrystal runs lab tests on pan-viral blockers - Stock Titan
Cocrystal Pharma Stock Slips: Why COCP’s Norovirus Bet Is Back in Focus - Bez Kabli
Cocrystal (COCP) Q1 2026 Earnings Miss by Significant: Key TakeawaysMargin Compression Risk - Newser
Why Is Cocrystal Pharma, Inc. (COCP) Stock Down Today? - Meyka
Cocrystal (COCP) Declines -3.57% Amid Market Weakness 2026-05-15Market Neutral Pair - newser.com
Cocrystal Pharma, Inc. 2026 Q1 Financials: Company Overview, Segment Information, and Going Concern Risks - Minichart
Cocrystal Pharma Releases Q1 2026 Financial Results - AlphaStreet
Cocrystal Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cocrystal Pharma, Inc. 1Q 2026: Net loss $(2.30M), No revenue — 10-Q Summary - TradingView
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Cocrystal Pharma, Inc. Quarterly Earnings Report - Stock Titan
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewswire
Number of shareholders of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Number of shareholders of Cocrystal Pharma Inc – LS:A3DWYX - TradingView
What Cocrystal (COCP) is building for next year | Q4 2025: EPS Exceeds ExpectationsSlow Growth - newser.com
Cocrystal Pharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
[EFFECT] Cocrystal Pharma, Inc. SEC Filing - Stock Titan
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection - The Manila Times
Cocrystal Showcases Norovirus Candidate CDI-988 at ICAR 2026 - TipRanks
Cocrystal Pharma (COCP) advances Fast Track CDI-988 in Phase 1b norovirus challenge study - Stock Titan
No approved norovirus drugs; Cocrystal tests oral CDI-988 - Stock Titan
COCP stock soars 75% — what is the link to Cocrystal’s norovirus treatment? - MSN
Cocrystal Pharma Incfiles to offer up to $150 million in securitiesSEC filing - marketscreener.com
Cocrystal Pharma (NASDAQ: COCP) files $150M shelf to offer stock and warrants - Stock Titan
COCP: Q4 2025 Earnings: Cocrystal Pharma Inc. posts 4.8% EPS beat with no Q4 revenueTop Analyst Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Cocrystal (COCP) Stock: Why Efficiency Gains (Momentum Building) 2026-04-22RSI Oversold Stocks - Xã Vĩnh Công
Why Cocrystal Pharma Shares Are Cooling Off Monday? - MSN
Form 8-KCurrent report - ADVFN
Cocrystal Pharma (COCP) price target increased by 33.33% to 8.16 - MSN
Smart Money: Can Cocrystal Pharma Inc deliver consistent EPS growth2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn
Investor Mood: Is Cocrystal Pharma Inc benefiting from innovation trendsQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
What events could move Cocrystal (COCP) Stock next | Price at $1.29, Down 9.79%Factor Momentum - Newser
Tech Rally: Is Cocrystal Pharma Inc stock risky to hold nowMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention - Zacks Small Cap Research
Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK
COCP PE Ratio & Valuation, Is COCP Overvalued - Intellectia AI
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - Yahoo Finance
Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight - meyka.com
What's Driving the Micro-Cap Mania in SKYQ and COCP - Kavout
Cocrystal Pharma Inc Azioni (COCP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cocrystal Pharma Inc Azioni (COCP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Director |
Feb 06 '26 |
Buy |
0.95 |
50,000 |
47,280 |
1,888,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 31 '25 |
Buy |
0.95 |
50,000 |
47,275 |
1,838,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 30 '25 |
Buy |
0.97 |
20,000 |
19,310 |
1,788,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 26 '25 |
Buy |
0.97 |
40,000 |
38,944 |
1,768,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 24 '25 |
Buy |
0.97 |
25,000 |
24,258 |
1,728,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 26 '25 |
Buy |
0.99 |
4,000 |
3,975 |
1,703,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 25 '25 |
Buy |
0.94 |
20,000 |
18,812 |
1,699,551 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):